Opens in a new tab

Another lever to growth — but of what?

Return To All Posts
  • 18/11/2026

    Floodgates open for unproven wellness drugs after US lifts peptide curbs

    Telehealth group Hims & Hers — which sells copycat weight-loss drugs — has also said it would start two peptides this month, with more expected to be added in the months ahead. The two substances aim to target ageing and athletic recovery, among other issues.

    Ryan MacDonald, an analyst at Needham, said the move offered Hims a new avenue for growth, following a 40 per cent fall in its share price this year. “Peptides can add another lever to growth,” MacDonald said. “Success with peptides will help the stock, I believe.”